| pubmed-article:18240390 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18240390 | lifeskim:mentions | umls-concept:C1334126 | lld:lifeskim |
| pubmed-article:18240390 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:18240390 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:18240390 | lifeskim:mentions | umls-concept:C0205549 | lld:lifeskim |
| pubmed-article:18240390 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:18240390 | pubmed:dateCreated | 2008-1-30 | lld:pubmed |
| pubmed-article:18240390 | pubmed:abstractText | The CXCR2 SAR of a series of bicyclic antagonists such as the 2-aminothiazolo[4,5-d]pyrimidine 3b was investigated by systematic variation of the fused pyrimidine-based heterocyclic cores. Replacement of the aminothiazole ring with a 2-thiazolone alternative led to a series of thiazolo[4,5-d]pyrimidine-2(3H)-one antagonists with markedly improved biological and pharmacokinetic properties, which are suitable pharmacological tools to probe the in vivo effects of CXCR2 antagonism combined with the associated CCR2 activity. | lld:pubmed |
| pubmed-article:18240390 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18240390 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18240390 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18240390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18240390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18240390 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18240390 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18240390 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:WaltersIainI | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:HillStevenS | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:CagePeterP | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:GrahamesCarol... | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:MartinIainI | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:EbdenMarkM | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:AustinCarolin... | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:HuntFraserF | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:AustinRupertR | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:BonnertRogerR | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:ChristieMarkM | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:JewellRobertR | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:GardinerStuar... | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:LewisShirleyS | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:David... | lld:pubmed |
| pubmed-article:18240390 | pubmed:author | pubmed-author:David... | lld:pubmed |
| pubmed-article:18240390 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18240390 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18240390 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:18240390 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18240390 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18240390 | pubmed:pagination | 798-803 | lld:pubmed |
| pubmed-article:18240390 | pubmed:meshHeading | pubmed-meshheading:18240390... | lld:pubmed |
| pubmed-article:18240390 | pubmed:meshHeading | pubmed-meshheading:18240390... | lld:pubmed |
| pubmed-article:18240390 | pubmed:meshHeading | pubmed-meshheading:18240390... | lld:pubmed |
| pubmed-article:18240390 | pubmed:meshHeading | pubmed-meshheading:18240390... | lld:pubmed |
| pubmed-article:18240390 | pubmed:meshHeading | pubmed-meshheading:18240390... | lld:pubmed |
| pubmed-article:18240390 | pubmed:meshHeading | pubmed-meshheading:18240390... | lld:pubmed |
| pubmed-article:18240390 | pubmed:meshHeading | pubmed-meshheading:18240390... | lld:pubmed |
| pubmed-article:18240390 | pubmed:meshHeading | pubmed-meshheading:18240390... | lld:pubmed |
| pubmed-article:18240390 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18240390 | pubmed:articleTitle | Evaluation of a series of bicyclic CXCR2 antagonists. | lld:pubmed |
| pubmed-article:18240390 | pubmed:affiliation | Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, United Kingdom. iain.walters@astrazeneca.com | lld:pubmed |
| pubmed-article:18240390 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18240390 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18240390 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18240390 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18240390 | lld:pubmed |
